Thymosin α-1

Thymosin α-1 (Thymalfasin) is a peptide (28 amino acids). The HEIVE catalog describes it as: Thymosin alpha-1 is listed in FDA compounding safety information. Country-specific registrations are not verified here. It is also known as Thymosin alpha-1, Zadaxin and Thymalfasin.

HEIVE groups Thymosin α-1 under immune balance, infection recovery, infection defense, immune ageing and inflammation. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Thymosin α-1 under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for Thymosin α-1 lists: Injection-site reaction; brief flu-like feeling. Longer-term concerns: Autoimmune flare risk in predisposed people — it modulates rather than suppresses. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Thymosin α-1 has no single onset time established by this catalog. The editorial timeline starts with “Days 1–14”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Thymosin α-1: 1.6 mg twice weekly for 4–8 weeks. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Thymosin α-1 as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists only injectable forms for Thymosin α-1; it does not establish that every studied or marketed form is injectable.

Preparation of Thymosin α-1 depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Thymosin α-1 depends on the specific formulation (injectable in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Thymosin α-1: Given in defined courses, not continuously. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Thymosin α-1 and Thymalin share the catalog categories immune balance, immune ageing and infection defense. Thymosin α-1: Thymosin alpha-1 is listed in FDA compounding safety information. Country-specific registrations are not verified here. Thymalin: A thymus extract from the same Soviet programme as Epithalon; long-term cohort claims are hard to verify. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Thymalin

The HEIVE editorial summary highlights: Sepsis mortality trials found benefit at doses chosen for hepatitis. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.